🔗 Share this article

A shadow economy for unlicensed slimming drugs is being driven by TikTok fitness influencers and sellers on communication apps, based on new investigations.

Experimental Drug Gaining Traction Via Social Media

The experimental drug, which remains in research studies, is being promoted by social media influencers for its alleged fat-burning effects. Viewers are encouraged to message these accounts directly for source information, while also obtaining discount codes.

Thriving Trade on Messaging Platforms

Separately, a flourishing trade exists on Telegram, where communities with thousands of participants share “before and after” images, injection guides and assertions of rapid UK delivery. Sellers market the substance there before redirecting customers to other platforms for transactions.

Learning About The Experimental Drug

Retatrutide is an experimental injectable created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies indicate it could help individuals lose up to a quarter of their total weight. Referred to as the “triple G”, the substance is being hailed online as the successor to Ozempic.

Healthcare Professionals Voice Worries

However, physicians and pharmacists have cautions that the sale of what is still an unlicensed drug in the UK is a cause for concern and could result in users administering substances of unknown origin.

Several professionals said the demand for the experimental drug could be connected to the rising price of approved slimming treatments such as Mounjaro.

Regulatory Position and Enforcement

Selling retatrutide on social media or messaging apps is illegal in the UK, as it is an unlicensed drug that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some influencers try to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still violate medicines, marketing, and customer regulations, potentially leading to penalties, prosecution or imprisonment.

Service Response and Content Elimination

Based on the social media company, the service has removed problematic material and banned related hashtags and query recommendations. The company said it was committed to maintaining the platform secure and allocating resources in enhancing compliance measures.

Online Trading Activities

Research also found groups with up to nine thousand members marketing retatrutide using the platform's integrated search feature, which operates like a online catalog. Entering “retatrutide” instantly brings up groups with thousands of members, populated with photos of slimming results, positive reviews and detailed instructions for mixing or injecting at home.

Within minutes of joining one group, a seller posted WhatsApp details, where the majority of purchases occur. The vendor sent an guidebook and guaranteed shipping within two days. When asked whether the substance was authentic, one vendor responded: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. None inquired about body mass, health issues or previous experience.

Product Details and Costs

Within these communities, posts display black plastic parcels with postal service stickers, stating to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, prepared at residence with purified liquid, or pre-filled injectors usually sold at 160 pounds for 20 milligrams. When asked how much time a pen should be used, sellers give contradictory responses varying between a several days to “depends on your body”.

Service Oversight and Safety Measures

A representative for Telegram said it actively monitored dangerous material on its platform including content that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“People are injecting substances they cannot confirm. Although the science behind this drug is valid, these digital versions may not contain what they claim,” stated a pharmacy expert, the head of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to recent cost increases for authorized slimming medications such as Mounjaro. “With costs rising, patients are using online platforms. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the environment they were produced in was clean,” she said.

Her staff has already seen patients injured by self-injection from unverified suppliers. “We understand the disappointment, but buying from messaging apps or communication platforms is gambling with your health,” said the doctor. “These materials could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from Eli Lilly stated the substance was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they said, noting that any product “falsely representing itself as a Lilly investigational product not yet authorized … may expose users to potentially serious health risks”.